Table 3.
Correlation of genetic mutations with the two group of patients (n = 44).
| Characteristic | Recurrence* | Control** | p-value |
|---|---|---|---|
| Patient, n (%) | 22 (50%) | 22 (50%) | |
| BRCA2 mutation | 22 (50%) | 22 (50%) | *** |
| APC mutation | 20 (49%) | 21 (51%) | >0.999 |
| ATM mutation | 19 (46%) | 22 (53%) | >0.999 |
| BRCA1 mutation | 18 (51%) | 17 (49%) | >0.999 |
| NF1 mutation | 12 (41%) | 17 (59%) | 0.203 |
| TET2 mutation | 16 (52%) | 15 (48%) | >0.999 |
| TSC1 mutation | 12 (63%) | 7 (37%) | 0.223 |
| TSC2 mutation | 12 (44%) | 15 (56%) | 0.537 |
| NOTCH1 mutation | 15 (45%) | 18 (55%) | 0.488 |
| MSH2 mutation | 10 (59%) | 7 (41%) | 0.537 |
| PTCH1 mutation | 13 (68%) | 6 (34%) | 0.067 |
| TP53 mutation | 22 (50%) | 22 (50%) | *** |
| PIK3CA mutation | 10 (56%) | 8 (44%) | 0.760 |
| FBXW7 mutation | 3 (37%) | 5 (63%) | 0.698 |
| RB1 mutation | 6 (55%) | 5 (45%) | >0.999 |
*Cancer recurrence within 24 months postoperatively. **No recurrence after 24 months postoperatively. ***p-values could not be calculated because every patient had BRCA2 and TP53 mutations.